Construction and validation of an NAD + metabolism-related lncRNA signature for predicting the prognosis and immune landscape of acute myeloid leukemia

References

• Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J (2013). 2020;103(3):38–40. PMID: 32236160.
   PubMedGoogle Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Estey EH. Acute myeloid leukemia: 2019 update on risk-stratification and management. Am J Hematol. 2018;93(10):1267–1291. doi:10.1002/ajh.25214
   PubMed Web of Science ®Google Scholar
• Newell LF, Cook RJ. Advances in acute myeloid leukemia. Br Med J. 2021;375:n2026, doi:10.1136/bmj.n2026
   PubMedGoogle Scholar
• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441, doi:10.1038/bcj.2016.50
   PubMed Web of Science ®Google Scholar
• Tamamyan G, Kadia T, Ravandi F, et al. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017;110:20–34. doi:10.1016/j.critrevonc.2016.12.004
   PubMed Web of Science ®Google Scholar
• Sun L, Suo C, Li ST, et al. Metabolic reprogramming for cancer cells and their microenvironment: beyond the Warburg effect. Biochim Biophys Acta Rev Cancer. 2018;1870(1):51–66. doi:10.1016/j.bbcan.2018.06.005
   PubMed Web of Science ®Google Scholar
• Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21(10):669–680. doi:10.1038/s41568-021-00378-6
   PubMed Web of Science ®Google Scholar
• Covarrubias AJ, Perrone R, Grozio A, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–141. doi:10.1038/s41580-020-00313-x
   PubMed Web of Science ®Google Scholar
• Ghanem MS, Monacelli F, Nencioni A. Advances in NAD-Lowering Agents for Cancer Treatment. Nutrients. 2021 May 14;13(5):1665. doi:10.3390/nu13051665.
   Google Scholar
• Jones CL, Stevens BM, Pollyea DA, et al. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. Cell Stem Cell. 2020;27(5):748–764.e4.e744. doi:10.1016/j.stem.2020.07.021
   PubMed Web of Science ®Google Scholar
• Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the In vivo evidence. Cell Metab. 2018;27(3):529–547. doi:10.1016/j.cmet.2018.02.011
   PubMed Web of Science ®Google Scholar
• Pramono AA, Rather GM, Herman H, et al. NAD- and NADPH-contributing enzymes as therapeutic targets in cancer: An overview. Biomolecules. 2020 Feb 26;10(3):358. doi:10.3390/biom10030358.
   Google Scholar
• Navas LE, Carnero A. NAD+ metabolism, stemness, the immune response, and cancer. Signal Transduct Target Ther. 2021;6(1):2, doi:10.1038/s41392-020-00354-w
   PubMed Web of Science ®Google Scholar
• Zapata-Pérez R, Wanders RJA, van Karnebeek CDM, et al. NAD+homeostasis in human health and disease. EMBO Mol Med. 2021;13(7):e13943, doi:10.15252/emmm.202113943
   PubMed Web of Science ®Google Scholar
• Lin L, Chen L, Xie Z, et al. Identification of NAD+ metabolism-derived gene signatures in ovarian cancer prognosis and immunotherapy. Front Genet. 2022;13:905238, doi:10.3389/fgene.2022.905238
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34, doi:10.1186/s13073-017-0424-2
   PubMed Web of Science ®Google Scholar
• Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61–68. doi:10.1016/j.canlet.2016.01.043
   PubMed Web of Science ®Google Scholar
• Hempel HA, Cuka NS, Kulac I, et al. Low intratumoral mast cells Are associated With a higher risk of prostate cancer recurrence. Prostate. 2017;77(4):412–424. doi:10.1002/pros.23280
   PubMed Web of Science ®Google Scholar
• Jones CL, Stevens BM, D’Alessandro A, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34(5):724–740.e4.e724. doi:10.1016/j.ccell.2018.10.005
   PubMed Web of Science ®Google Scholar
• Xie N, Zhang L, Gao W, et al. NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential. Signal Transduct Target Ther. 2020;5(1):227, doi:10.1038/s41392-020-00311-7
   PubMed Web of Science ®Google Scholar
• Chiarugi A, Dölle C, Felici R, et al. The NAD metabolome — a key determinant of cancer cell biology. Nat Rev Cancer. 2012;12(11):741–752. doi:10.1038/nrc3340
   PubMed Web of Science ®Google Scholar
• Sun J, Li W, Sun Y, et al. A novel antisense long noncoding RNA within the IGF1R gene locus is imprinted in hematopoietic malignancies. Nucleic Acids Res. 2014;42(15):9588–9601. doi:10.1093/nar/gku549
   PubMed Web of Science ®Google Scholar
• Papaioannou D, Nicolet D, Ozer HG, et al. Prognostic and biologic relevance of clinically applicable long noncoding RNA profiling in older patients with cytogenetically normal acute myeloid leukemia. Mol Cancer Ther. 2019;18(8):1451–1459. doi:10.1158/1535-7163.MCT-18-1125
   PubMed Web of Science ®Google Scholar
• Garzon R, Volinia S, Papaioannou D, et al. Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A. 2014;111(52):18679–18684. doi:10.1073/pnas.1422050112
   PubMed Web of Science ®Google Scholar
• Dong C, Zhang N, Zhang L. The multi-omic prognostic model of oxidative stress-related genes in acute myeloid leukemia. Front Genet. 2021;12:722064, doi:10.3389/fgene.2021.722064
   PubMed Web of Science ®Google Scholar
• Huang L, Lin L, Fu X, et al. Development and validation of a novel survival model for acute myeloid leukemia based on autophagy-related genes. PeerJ. 2021;9:e11968, doi:10.7717/peerj.11968
   PubMed Web of Science ®Google Scholar
• Wang J, Zhuo Z, Wang Y, et al. Identification and validation of a prognostic risk-scoring model based on ferroptosis-associated cluster in acute myeloid leukemia. Front Cell Dev Biol. 2022;9:800267, doi:10.3389/fcell.2021.800267
   PubMed Web of Science ®Google Scholar
• Han C, Zheng J, Li F, et al. Novel prognostic signature for acute myeloid leukemia: bioinformatics analysis of combined CNV-driven and ferroptosis-related genes. Front Genet. 2022;13:849437, doi:10.3389/fgene.2022.849437
   PubMedGoogle Scholar
• Liu S, Luo D, Luo J, et al. Construction of a pyroptosis-related signature for prognostic prediction and characterization of immune microenvironment in acute myelogenous leukemia. Int J Gen Med. 2022;Volume 15:2913–2927. doi:10.2147/IJGM.S352062
   Web of Science ®Google Scholar
• Nie L, Zhang Y, You Y, et al. The signature based on seven genomic instability-related genes could predict the prognosis of acute myeloid leukemia patients. Hematology. 2022;27(1):833–841. doi:10.1080/16078454.2022.2107970
   Web of Science ®Google Scholar
• Shao R, Wang H, Wang J, et al. Comprehensive analysis of a pyroptosis-related gene signature of clinical and biological value in acute myeloid leukaemia. Int Immunopharmacol. 2022;108:108802, doi:10.1016/j.intimp.2022.108802
   PubMed Web of Science ®Google Scholar
• Xu Q, Guo T. Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia. Hematology. 2022;27(1):659–671. doi:10.1080/16078454.2022.2056677
   PubMed Web of Science ®Google Scholar
• Zhang P, Tan X, Zhang D, et al. Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis. PLoS One. 2021;16(5):e0249951, doi:10.1371/journal.pone.0249951
   PubMed Web of Science ®Google Scholar
• Han L, Hao Y, Wang J, et al. Knockdown of LINC02465 suppresses gastric cancer cell growth and metastasis Via PI3K/AKT pathway. Hum Gene Ther Clin Dev. 2019;30(1):19–28. doi:10.1089/humc.2018.177
   PubMed Web of Science ®Google Scholar
• Yang L, Chen Y, Liu N, et al. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN. J Hematol Oncol. 2021;14(1):46, doi:10.1186/s13045-021-01059-5
   PubMed Web of Science ®Google Scholar
• He R, Wu S, Gao R, et al. Identification of a Long Noncoding RNA TRAF3IP2-AS1 as Key regulator of IL-17 signaling through the SRSF10–IRF1–Act1 axis in autoimmune diseases. J Immunol. 2021;206(10):2353–2365. doi:10.4049/jimmunol.2001223
   PubMed Web of Science ®Google Scholar
• Li J, Zhang J, Tao S, et al. Prognostication of pancreatic cancer using the cancer genome atlas based ferroptosis-related long Non-coding RNAs. Front Genet. 2022;13:838021, doi:10.3389/fgene.2022.838021
   PubMed Web of Science ®Google Scholar
• Shi R, Wang Z, Zhang J, et al. N6-Methyladenosine-related long noncoding RNAs as potential prognosis biomarkers for endometrial cancer. Int J Gen Med. 2021;Volume 14:8249–8262. doi:10.2147/IJGM.S336403
   Web of Science ®Google Scholar
• Zan XY, Li L. Construction of lncRNA-mediated ceRNA network to reveal clinically relevant lncRNA biomarkers in glioblastomas. Oncol Lett. 2019;17(5):4369–4374. doi:10.3892/ol.2019.10114
   PubMed Web of Science ®Google Scholar
• Zhong F, Yao F, Cheng Y, et al. m6A-related lncRNAs predict prognosis and indicate immune microenvironment in acute myeloid leukemia. Sci Rep. 2022;12(1):1759, doi:10.1038/s41598-022-05797-5
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566. doi:10.1158/0008-5472.CAN-18-3962
   PubMed Web of Science ®Google Scholar
• Barbosa K, Li S, Adams PD, et al. The role of TP53 in acute myeloid leukemia: challenges and opportunities. Genes Chromosomes Cancer. 2019;58(12):875–888. doi:10.1002/gcc.22796
   PubMed Web of Science ®Google Scholar
• Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol Cancer Ther. 2017;16(11):2598–2608. doi:10.1158/1535-7163.MCT-17-0386
   PubMed Web of Science ®Google Scholar
• Xia L, Oyang L, Lin J, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20(1):28, doi:10.1186/s12943-021-01316-8
   PubMed Web of Science ®Google Scholar
• Tabe Y, Konopleva M. Role of microenvironment in resistance to therapy in AML. Curr Hematol Malig Rep. 2015;10(2):96–103. doi:10.1007/s11899-015-0253-6
   PubMed Web of Science ®Google Scholar
• Chen Z, Zhou L, Liu L, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun. 2020;11(1):5077, doi:10.1038/s41467-020-18916-5
   PubMed Web of Science ®Google Scholar
• Ugel S, Canè S, De Sanctis F, et al. Monocytes in the tumor microenvironment. Annu Rev Pathol. 2021;16:93–122. doi:10.1146/annurev-pathmechdis-012418-013058
   PubMed Web of Science ®Google Scholar
• Varol C, Mildner A, Jung S. Macrophages: development and tissue specialization. Annu Rev Immunol. 2015;33:643–675. doi:10.1146/annurev-immunol-032414-112220
   PubMed Web of Science ®Google Scholar
• Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol. 2009;9(3):185–194. doi:10.1038/nri2508
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang X, Qi P, et al. Tumor microenvironmental competitive endogenous RNA network and immune cells Act as robust prognostic predictor of acute myeloid leukemia. Front Oncol. 2021;11:584884, doi:10.3389/fonc.2021.584884
   PubMed Web of Science ®Google Scholar
• Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. Clin Rev Allergy Immunol. 2020;58(3):313–325. doi:10.1007/s12016-019-08753-w
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5(11):e646, doi:10.1097/HS9.0000000000000646
   PubMed Web of Science ®Google Scholar